

To: [redacted] 5.1.2e | 5.1.2e | 5.1.2e | @rivm.nl]
From: [redacted] 5.1.2e | 5.1.2e
Sent: Mon 12/14/2020 1:31:18 PM
Subject: FW: PHIRI WP8 Rapid Exchange Forum
Received: Mon 12/14/2020 1:31:19 PM
[Evaluation of Abbott Panbio rapid antigen test3.pptx](#)
[Evaluation of Abbotts Panbio COVID-19 rapid antigen test in Norway \(1\).pdf](#)

Hoi [redacted] 5.1.2e

Sinds 1 november loopt PHIRI: de Population Health Information Research Infrastructure for COVID-19 (41 partners in 30 landen, veel NPHI's betrokken).

Zie de website (in ontwikkeling) voor meer informatie: <https://www.phiri.eu/>.

We leiden zelf een werkpakket over Foresight (WP9), zie onderstaande plaatje.

Maar nu mail ik je over WP8.

Daarin komen de landen om de week op maandag bij elkaar om informatie uit te wisselen, behoefte-gestuurd. Als je een vraag hebt, kun je die indienen en dan geven andere landen er antwoord op.

Dit is in het begin van de pandemie al enigszins provisorisch opgezet in de Joint Action on Health Information (InfAct), en wordt nu in dit project wat verder/professioneler uitgewerkt.

Vragen tot nu toe gingen bijv. over back-to-school policy, systems for contact tracing, testing at airports, counting of COVID-19 deaths, vaccine prioritization lists.

De vragen komen meestal enkele dagen voor de meeting beschikbaar. Ze worden dan door de landen in de meeting beantwoord of ervoor/erna via mail.


MIJN VRAAG AAN JOU: Ik zou hiervoor graag een sparring partner willen bij CIB. Weet jij iemand? Veel info kan ik zelf opzoeken via rivm.nl of rijksoverheid.nl... maar niet alles. En wellicht zit er voor CIB ook interessante informatie tussen – hoewel er natuurlijk eigen kanalen van informatie-uitwisseling zijn, dat snap ik wel.

Ik voeg ter illustratie nog een aanvulling van Noorwegen toe op vragen over counting of Rapid Antigen Tests. Are negative tests captured too? Are they included with the number of tests reported to ECDC on TESSy? Are cases detected on Rapid Antigen Tests included in the case notification numbers?

Hartelijke groet,

[redacted] 5.1.2e

National Institute for Public Health and the Environment (RIVM)
PO Box 1 | 3720 BA Bilthoven | The Netherlands
Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | The Netherlands
T: +31 (0)6 [redacted] 5.1.2e | +31 (0)30 [redacted] 5.1.2e
E: [redacted] 5.1.2e | @rivm.nl | W: www.rivm.nl
Monday-Tuesday-Thursday-Friday



From: 5.1.2e, 5.1.2e <5.1.2e@fhi.no>

Sent: maandag 14 december 2020 11:54

To: 5.1.2e, 5.1.2e <5.1.2e@iss.it>; 5.1.2e <5.1.2e@aek.hu>; PHIRI.Austria <5.1.2e@goeg.at>; 5.1.2e <5.1.2e@goeg.at>; 5.1.2e <5.1.2e@goeg.at>; 5.1.2e <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@zzjfbih.ba>; 5.1.2e <5.1.2e@zzjfbih.ba>; 5.1.2e <5.1.2e@zzjfbih.ba>; 5.1.2e <5.1.2e@ncpha.government.bg>; 5.1.2e <5.1.2e@ncpha.government.bg>; 5.1.2e <5.1.2e@hzjz.hr>; 5.1.2e <5.1.2e@hzjz.hr>; 5.1.2e <5.1.2e@uzis.cz>; 5.1.2e <5.1.2e@uzis.cz>; 5.1.2e <5.1.2e@tai.ee>; 5.1.2e <5.1.2e@tai.ee>; 5.1.2e <5.1.2e@sm.ee>; 5.1.2e <5.1.2e@sm.ee>; 5.1.2e <5.1.2e@tai.ee>; 5.1.2e <5.1.2e@thl.fi>; 5.1.2e <5.1.2e@santepubliquefrance.fr>; 5.1.2e <5.1.2e@santepubliquefrance.fr>; 5.1.2e <5.1.2e@santepubliquefrance.fr>; 5.1.2e <5.1.2e@rki.de>; 5.1.2e <5.1.2e@rki.de>; ΕΟΠΥΥ/Γεωργακοπούλου Χριστίνα <5.1.2e@eopyy.gov.gr>; 5.1.2e <5.1.2e@med.uoc.gr>; 5.1.2e <5.1.2e@gmail.com>; 5.1.2e <5.1.2e@eopyy.gov.gr>; 5.1.2e <5.1.2e@eopyy.gov.gr>; Láng Róbert <5.1.2e@aek.hu>; 5.1.2e <5.1.2e@gmail.com>; 5.1.2e <5.1.2e@aek.hu>; 5.1.2e <5.1.2e@health.gov.ie>; 5.1.2e <5.1.2e@hrb.ie>; 5.1.2e <5.1.2e@hrb.ie>; 5.1.2e <5.1.2e@health.gov.ie>; 5.1.2e <5.1.2e@hse.ie>; 5.1.2e <5.1.2e@iss.it>; 5.1.2e <5.1.2e@spkc.gov.lv>; 5.1.2e <5.1.2e@spkc.gov.lv>; 5.1.2e <5.1.2e@sam.lt>; 5.1.2e <5.1.2e@gov.mt>; 5.1.2e <5.1.2e@helsedir.no>; 5.1.2e <5.1.2e@helsedir.no>; 5.1.2e <5.1.2e@mz.gov.pl>; 5.1.2e <5.1.2e@mz.gov.pl>; 5.1.2e <5.1.2e@medicina.ulisboa.pt>; 5.1.2e <5.1.2e@ihmt.unl.pt>; 5.1.2e <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@batut.org.rs>; 5.1.2e <5.1.2e@batut.org.rs>; 5.1.2e <5.1.2e@nczisk.sk>; 5.1.2e <5.1.2e@nijz.si>; 5.1.2e <5.1.2e@nijz.si>; 5.1.2e <5.1.2e@nijz.si>; 5.1.2e <5.1.2e@nijz.si>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@eu-isciii.es>; 5.1.2e <5.1.2e@aragon.es>; 5.1.2e <5.1.2e@aragon.es>; 5.1.2e <5.1.2e@aragon.es>; 5.1.2e <5.1.2e@aragon.es>; 5.1.2e <5.1.2e@aragon.es>; 5.1.2e <5.1.2e@aragon.es>; 5.1.2e <5.1.2e@folkhalsomyndigheten.se>; 5.1.2e <5.1.2e@folkhalsomyndigheten.se>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@swansea.ac.uk>; 5.1.2e <5.1.2e@swansea.ac.uk>; 5.1.2e <5.1.2e@goeg.at>; 5.1.2e <5.1.2e@isciii.es' <5.1.2e@isciii.es>; 5.1.2e <5.1.2e@sciensano.be' <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@sciensano.be>; 5.1.2e <5.1.2e@ecdc.europa.eu' <5.1.2e@ecdc.europa.eu>; 5.1.2e <5.1.2e@ecdc.europa.eu' <5.1.2e@ecdc.europa.eu>; 5.1.2e <5.1.2e@gmail.com' <5.1.2e@gmail.com>; 5.1.2e <5.1.2e@insp.gov.ro' <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@insp.gov.ro>; 5.1.2e <5.1.2e@rivm.nl>; **Cc:** 5.1.2e <5.1.2e@fhi.no>; 5.1.2e <5.1.2e@hzjz.hr>; 5.1.2e <5.1.2e@health.gov.ie>; 5.1.2e <5.1.2e@health.gov.ie>; 5.1.2e <5.1.2e@fhi.no>; 5.1.2e <5.1.2e@mz.gov.pl>; 5.1.2e <5.1.2e@gmail.com>; 5.1.2e <5.1.2e@gmail.com>; 5.1.2e <5.1.2e@fhi.no>; 5.1.2e <5.1.2e@fhi.no>; 5.1.2e <5.1.2e@fhi.no>

Subject: SV: PHIRI WP8 Rapid Exchange Forum

Dear 5.1.2e dear all,

As mentioned in the meeting, please find attached a presentation and the report from the 5.1.2a validation study about the Abbot Rapid Antigen Test.

The work has been led by [REDACTED] 5.1.2e from the Norwegian Institute of Public Health.

Best wishes,

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] 5.1.2e

[REDACTED] 5.1.2e

P.O.Box 4404 Nydalen, 0403 Oslo

Address: Lovisenberggt 8

Tel +47 [REDACTED] 5.1.2e | Mob: +47 [REDACTED] 5.1.2e

www.fhi.no

Dear Colleagues,

as previously announced, the bi-weekly meetings on COVID-19 that started in the course of the Joint Action InfAct are now shifted to PHIRI – Population Health Information Research Infrastructure for COVID-19 – WP8 Rapid Exchange Forum. We are pleased to invite you to the bi-weekly meetings promoting regular information exchange on COVID-19 between countries.

To participate in the video conference, please **click on the following link** and follow the instructions

<https://gesundheitoesterreichgmbh-ipq.my.webex.com/gesundheitoesterreichgmbh-ipq.my/j.php?MTID=mbfc8a3bb97f92b2341f588bf0d76cc25>

Meeting number: [REDACTED] 5.1.2h

Password: [REDACTED] 5.1.2h

If you should dial in **via telephone**, you can find the available call-in numbers [here](#). The following access code is required [REDACTED] 5.1.2h

If you are requested to install WebEx, you can also open WebEx via your Internet browser.

As soon as the application is open, connect your audio with a click on the phone receiver and click on the camera icon to start your webcam if necessary.

If you have specific topics or questions you would like to discuss in the course of the meetings, please email them to [REDACTED] 5.1.2e [@goeg.at](mailto:[REDACTED]@goeg.at) until 24 h before the meeting.

We are looking forward to your participation.

Kind regards,

[REDACTED] 5.1.2e

Meeting Code & General Information

Please note the configuration/access for integrated/external camera and loudspeaker/microphone or headset. You can get in to test your equipment 15 minutes before the meeting starts.

1. Set your microphone to "mute" at the beginning of the meeting.

2. Avoid background noise and/or activate your microphone only when you are at the floor. Speak clearly, slowly and distinctly at a normal volume
3. Disconnect when the meeting has been declared over by the chairpersons.
4. If you have any problems (including during the meeting), contact [Name, e-mail address and/or phone number, if applicable] or use the chat feature.
5. If the connection is interrupted during the meeting for technical reasons, we will send a new link via the invitation distribution list.

By participating in this WebEx meeting, you acknowledge that the information you provide, including, but not limited to, first name, last name, title and email address, will be provided to WebEx for processing in accordance with their privacy policy. Gesundheit Österreich GmbH stores the information provided for the WebEx meeting, in particular your e-mail address, exclusively for the duration of the meeting.


You are basically entitled to the rights of information, correction, deletion, restriction, data transferability and objection. See Chapter III EU-DSC-VO Rights of the person concerned (<https://www.datenschutz-grundverordnung.eu/>).

This WebEx service offers a function for recording audio data and documents or other materials exchanged or displayed during the meeting. The moderator of the meeting will explicitly inform all participants before using this function. You may object to such a recording at any time. Then you can decide together whether to refrain from recording or whether you prefer not to participate in the session. Please note that such recordings can be used as evidence in case of a legal dispute.

If you have any questions about this, please contact 5.1.2e@qoeq.at.

Ezen üzenet és annak bármely csatolt anyaga bizalmas, jogi védelem alatt áll, a nyilvános közléstől védett. Az üzenetet kizárólag a címzett, illetve az általa meghatalmazottak használhatják fel. Ha Ön nem az üzenet címzettje, úgy kérjük, hogy telefonon, vagy e-mail-ben értesítse erről az üzenet küldőjét és törölje az üzenetet, valamint annak összes csatolt mellékletét a rendszeréből. Ha Ön nem az üzenet címzettje, abban az esetben tilos az üzenetet vagy annak bármely csatolt mellékletét lemásolnia, elmentenie, az üzenet tartalmát bárkivel közölnie vagy azzal visszaélnie.

This message and any attachment are confidential and are legally privileged. It is intended solely for the use of the individual or entity to whom it is addressed and others authorised to receive it. If you are not the intended recipient, please telephone or email the sender and delete this message and any attachment from your system. Please note that any dissemination, distribution, copying or use of or reliance upon the information contained in and transmitted with this e-mail by or to anyone other than the recipient designated above by the sender is unauthorised and strictly prohibited.



Dona il tuo **5 per mille** per la ricerca sanitaria
all'**ISTITUTO SUPERIORE DI SANITÀ**. Codice fiscale **80211730587**

SIAMO SEMPRE CON TE. LA NOSTRA RICERCA È LA TUA SALUTE